Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9701986 | 0.82 | MAPT (0.53) | MRGPRX4FFAR4MAPTTDP1L3MBTL1 | |
| SCHEMBL3608836 | 0.81 | FFAR4 (0.49) | MRGPRX4FFAR4MAPTTDP1L3MBTL1 | |
| SCHEMBL6097656 | 0.81 | MRGPRX4 (0.53) | MRGPRX4FFAR4MAPTTDP1L3MBTL1 | |
| SCHEMBL25081934 | 0.81 | MAPT (0.64) | MRGPRX4FFAR4MAPTTDP1L3MBTL1 | |
| SCHEMBL31197229 | 0.81 | MRGPRX4 (0.64) | MRGPRX4FFAR4NPC1RXRARXRB | |
| SCHEMBL25946416 | 0.79 | MRGPRX4 (0.51) | MRGPRX4FFAR4MAPTTDP1L3MBTL1 | |
| SCHEMBL27090028 | 0.79 | LIPE (0.58) | MRGPRX4FFAR4MAPTTDP1L3MBTL1 | |
| SCHEMBL21835674 | 0.78 | MRGPRX4 (0.53) | MRGPRX4FFAR4MAPTTDP1L3MBTL1 | |
| SCHEMBL16096378 | 0.78 | ERN1 (0.51) | MRGPRX4FFAR4MAPTTDP1L3MBTL1 | |
| SCHEMBL11163647 | 0.77 | LMNA (0.55) | MAPTTDP1L3MBTL1MAPK1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087602-B2 | Cinnoline derivatives and use as medicine | ASTRAZENECA UK LIMITED (GB) | 2006-08-08 | — | — | US | disclosed |
| CN-1252054-C | Qinoline derivatives inhibiting effect of growth factors such as VEGF | ZENECA LTD (GB) | 2006-04-19 | — | — | CN | disclosed |
| EP-0888310-B1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | EP | disclosed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | ZENECA LIMITED | 2003-10-23 | — | — | US | disclosed |
| US-6514971-B1 | For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans | ZENECA LIMITED (GB) | 2003-02-04 | — | — | US | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| EP-0888310-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997034876-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | VEGFA, CNR1, CCR7 | MRGPRX4 830/4885FFAR4 949/4885MAPT 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.